Accueil
Marchés
Graphique & Idées
Algo
Nouvelles
Store
Courtiers
Télécharger
Calendrier Economique
Signaux de trading
Terminal Web
Tapez
/
pour rechercher : @user, $symbol
Recherche
Se connecter
Créer un compte
Français
English
Русский
中文
Español
Português
日本語
Deutsch
한국어
Italiano
Türkçe
CCCC
#2959
C4 Therapeutics, Inc.
2.7
0
-1.46%
Secteur:
Base:
Devise de Profit:
Range quotidien
Range Annuel
Changement quotidien
-1.46%
Changement Mensuel
+26.17%
Evolution sur 6 mois
+5.06%
Changement Annuel
+4.25%
Clôture Précédente
2.7
4
Open
2.7
0
Bid
Ask
Low
2.7
0
High
2.7
0
Volume
57
Marchés
Actions des Marchés US
Soins de Santé
CCCC
Open full chart
Financials
Overview
Relevé
Statistics
Dividends
Quarterly
Annual
Value
2020
2021
2022
2023
2024
2025
TTM
Key stats
Total common shares outstanding
43.12 M
48.74 M
49.05 M
68.6 M
70.99 M
97.58 M
—
Valuation ratios
Enterprise value
1.25 B
1.49 B
283.19 M
320.69 M
200.06 M
111.77 M
354.05 M
Price to earnings ratio
—
—
-2.44
-2.44
-2.37
-1.5
-4.81
Price to sales ratio
—
—
10.03
15.59
7.02
—
—
Price to cash flow ratio
—
—
2.94
3.03
3.83
1.6
5.82
Price to book ratio
—
—
1.08
1.32
1.16
0.62
1.07
Enterprise value to EBITDA ratio
—
—
—
—
—
—
—
Profitability ratios
Return on assets %
0.17
0.17
0.3
0.35
0.3
0.29
0.35
Return on equity %
0.24
0.22
0.44
0.54
0.49
0.41
0.57
Return on invested capital %
460.27
313.53
258.91
346.35
357.39
364.29
418.25
Gross margin %
—
—
100
100
100
100
400
Operating margin %
—
—
416.56
669.84
336.15
320.53
1 360.45
EBITDA margin %
—
—
—
—
—
—
—
Net margin %
—
—
412.19
638.34
295.96
292.08
1 238.66
Liquidity ratios
Quick ratio
—
—
—
—
—
—
—
Current ratio
8.69
6.36
6.46
6.34
5.71
7.81
24.32
Inventory turnover
—
—
—
—
—
—
—
Asset turnover
—
—
0.07
0.05
0.1
0.1
0.12
Solvency ratios
Debt to assets ratio
—
—
—
—
—
—
—
Debt to equity ratio
—
—
—
—
—
—
—
Long term debt to total assets ratio
0.03
0.02
0.02
0
—
—
—
Long term debt to total equity ratio
0.04
0.03
0.03
0
—
—
—
Per share metrics
Operating cash flow per share
—
—
2.17
2.15
0.94
1.19
1.34
EBIT per share
—
—
—
—
—
—
—
EBITDA per share
—
—
—
—
—
—
—
Total debt per share
—
—
—
—
—
—
—
Cash per share
—
—
6.9
5.67
3.85
3.58
12.79
Net current asset value per share
—
—
5.89
5.46
3.72
3.11
12.41
Tangible book value per share
—
—
5.92
4.96
3.11
3.1
10.43
Working capital per share
—
—
4.97
4.6
3.06
2.72
10.32
Book value per share
—
—
5.92
4.96
3.11
3.1
10.43
Nouvelles
Barclays relève l’objectif de cours de C4 Therapeutics suite aux progrès des essais
Barclays raises C4 Therapeutics stock price target on trial progress
TD Cowen réitère sa recommandation d’achat sur C4 Therapeutics
TD Cowen reiterates Buy rating on C4 Therapeutics stock
Le BPA de C4 a dépassé les attentes de 0,11$, le CA a surpassé les prévisions
C4 earnings beat by $0.11, revenue topped estimates
Brookline Capital relève l’objectif de cours de C4 Therapeutics suite aux progrès des essais
Brookline Capital raises C4 Therapeutics stock price target on trial progress
C4 Therapeutics administre le traitement au premier patient de son essai de phase 2 sur le myélome
C4 Therapeutics doses first patient in phase 2 myeloma trial
Le directeur médical de C4 Therapeutics, Reyno, vend des actions pour 22.200€
C4 Therapeutics’ chief medical officer Reyno sells $22,200 in stock